Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of January 2021, with a specific reporting date of January 19, 2021. The document serves as a transaction notification regarding share acquisitions by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with them.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics for the company. It exclusively details specific share transaction data:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: GBP 14.0488 per share.
- Transaction Date: January 18, 2021.
- Transaction Venue: London Stock Exchange (XLON).
- Total Volume: Approximately 13,293 shares acquired across 13 individuals.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine compliance notifications for share acquisitions resulting from dividend reinvestment plans. There is no comparative data provided against prior periods.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, outlook, risk factors, or contingencies. The transactions are described strictly as "Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021."
Investor Verification Checklist
- Verify the dividend reinvestment plan terms and the ex-dividend date of January 14, 2021.
- Confirm the market price of GSK ordinary shares on the London Stock Exchange on January 18, 2021, to validate the reported transaction price of GBP 14.0488.
- Review the specific roles of the 13 PDMRs and PCAs listed to ensure alignment with internal governance disclosures.
- Note that this filing does not provide any operational or financial performance data for the period.